Fox Run Management L.L.C. Purchases Shares of 11,841 Kodiak Sciences Inc. (NASDAQ:KOD)

Fox Run Management L.L.C. acquired a new stake in shares of Kodiak Sciences Inc. (NASDAQ:KOD) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 11,841 shares of the company’s stock, valued at approximately $118,000.

Several other large investors have also modified their holdings of KOD. PNC Financial Services Group Inc. increased its position in Kodiak Sciences by 1,501.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company’s stock worth $32,000 after purchasing an additional 2,988 shares during the last quarter. US Bancorp DE purchased a new stake in shares of Kodiak Sciences during the 4th quarter valued at $40,000. JPMorgan Chase & Co. grew its stake in shares of Kodiak Sciences by 220.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company’s stock valued at $117,000 after buying an additional 30,735 shares during the period. SG Americas Securities LLC increased its holdings in shares of Kodiak Sciences by 61.4% during the 4th quarter. SG Americas Securities LLC now owns 20,684 shares of the company’s stock worth $206,000 after buying an additional 7,871 shares during the last quarter. Finally, Barclays PLC grew its position in Kodiak Sciences by 65.5% during the third quarter. Barclays PLC now owns 79,658 shares of the company’s stock valued at $208,000 after acquiring an additional 31,527 shares during the period. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group upgraded Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a report on Monday, December 9th.

Kodiak Sciences Price Performance

Shares of NASDAQ KOD opened at $2.91 on Friday. Kodiak Sciences Inc. has a 1-year low of $2.19 and a 1-year high of $11.60. The company has a market capitalization of $153.14 million, a price-to-earnings ratio of -0.80 and a beta of 2.26. The business has a 50-day moving average of $4.85 and a 200-day moving average of $5.40.

Kodiak Sciences (NASDAQ:KOD) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.06. Research analysts expect that Kodiak Sciences Inc. will post -3.45 EPS for the current fiscal year.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.